摘要
目的探讨通心络胶囊联合瑞舒伐他汀钙对冠心病心绞痛患者内皮素-1(ET-1)、一氧化氮(NO)、肌钙蛋白I(cTnI)、血管性假性血友病因子(vWF)水平的影响。方法选择2018年1月至2019年12月我院救治的124例冠心病心绞痛患者作为研究对象,根据抽签法将其分为对照组与观察组,各62例。对照组给予常规治疗加瑞舒伐他汀钙,观察组在对照组基础上给予通心络胶囊。比较两组患者的临床疗效及治疗前、后的血栓前状态指标、vWF、NO、cTnI、ET-1水平、心功能指标。结果观察组的治疗总有效率为96.77%,高于对照组的85.48%,差异具有统计学意义(P<0.05)。治疗后,两组的AA、ADP诱导血小板聚集值、FIB、D-D水平均降低,且观察组低于对照组,差异具有统计学意义(P<0.05)。治疗后,两组的vWF、cTnI、ET-1水平均降低,NO水平升高,且观察组优于对照组,差异具有统计学意义(P<0.05)。治疗后,两组的LVEDD、LVESD均降低,LVEF、CI均升高,且观察组优于对照组,差异具有统计学意义(P<0.05)。结论通心络胶囊联合瑞舒伐他汀钙治疗冠心病心绞痛患者的效果显著,可有效改善血栓前状态,调整vWF、NO、cTnI、ET-1水平,促进心功能恢复,值得临床推广应用。
Objective To explore the effects of Tongxinluo capsule combined with rosuvastatin calcium on endothelin-1(ET-1),nitric oxide(NO),troponin I(cTnI)and von willebrand factor(vWF)in patients with coronary heart disease and angina pectoris.Methods A total of 124 patients with coronary heart disease and angina pectoris treated in our hospital from January 2018 to December 2019 were selected as the research objects.The patients were divided into control group and observation group according to the drawing lots method,with 62 cases in each group.The control group was given routine treatment+rosuvastatin calcium,and the observation group was given Tongxinluo capsule on the basis of the control group.The clinical efficacy,prethrombotic state indexes,vWF,NO,cTnI,ET-1 levels and cardiac function indexes before and after treatment were compared between the two groups.Results The total effective rate of treatment in the observation group was 96.77%,which was higher than 85.48%in the control group,and the difference was statistically significant(P<0.05).After treatment,the platelet aggregation value induced by AA and ADP,FIB and D-D levels in the two groups decreased,and those in the observation group were lower than the control group,the differences were statistically significant(P<0.05).After treatment,the vWF,cTnI and ET-1 levels in the two groups decreased,the NO level increased,and those in the observation group were better than the control group,the differences were statistically significant(P<0.05).After treatment,LVEDD and LVESD in the two groups decreased,LVEF and CI increased,and those in the observation group were better than the control group,the differences were statistically significant(P<0.05).Conclusion Tongxinluo capsule combined with rosuvastatin calcium in the treatment of patients with coronary heart disease and angina pectoris has a significant effect,it can effectively improve the prethrombotic state,adjust the levels of vWF,NO,cTnI and ET-1,and promote the recovery of cardiac function,which is worthy of clinical promotion and application.
作者
孙杰
刘欣
SUN Jie;LIU Xin(Affiliated Baoji Hospital of Xi'an Medical University,Baoji 721000;People's Hospital of Ganquan County,Yan'an 716100,China)
出处
《临床医学研究与实践》
2022年第3期134-137,共4页
Clinical Research and Practice
关键词
通心络胶囊
瑞舒伐他汀钙
冠心病
心绞痛
血栓前状态
Tongxinluo capsule
rosuvastatin calcium
coronary heart disease
angina pectoris
prethrombotic state
